A clinical decision report appraising:
Schwartz CL, Wexler LH, Krailo MD, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63(1):54-615. https://doi.org/10.1002/pbc.25753
for a patient with osteosarcoma and concerns about the risk of secondary malignant neoplasms that attend use of dexarazoxane.
Creative Commons License
This work is licensed under a Attribution 4.0 International (CC-BY 4.0) License
PRZYBYCIEN TS. Dexrazoxane decreases the cardiotoxic effects of doxorubicin in osteosarcoma patients without increasing mortality from secondary malignant neoplasms. Clin. Res. Prac. May 28 2021;7(1):eP2673. https://doi.org/10.22237/crp/1622160360